Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

ResMed launches AirSense 11, to advance digital health in sleep apnoea for Indians: Our Bureau, Bengaluru Monday, January 6, 2025, 17:30 Hrs [IST] ResMed, the world’s leading he ...

OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common ...

Investing.com -- Goldman Sachs initiated coverage on ResMed Inc (NYSE ... strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

In the latest quarter, 5 analysts provided ratings for ResMed RMD, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how ...

ResMed actually specializes in ventilators, for example against sleep apnoea. Now comes the first end customer product for ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...

ResMed is best known for creating medical devices for treating diseases such as sleep apnea and COPD. This includes making masks that are used with devices like CPAP machines, designed to be ...